Webinar
Gut Health and Your Microbiome: Separating Facts from Fiction
Join us for an enlightening webinar, “Gut Health and Your Microbiome: Separating Facts from Fiction,” where Alumni Ventures HealthTech Fund Managing Partner David Shapiro and guests will delve into the intricacies of gut health.
See video policy below.
Post Webinar Summary
In this webinar, David Shapiro, a managing partner at Alumni Ventures, hosts a conversation with CEOs Leo Grady of Jonah Health and Colleen Cutcliffe of Pendulum. They explore the importance of gut health and the microbiome, emphasizing its influence beyond digestion, including its links to metabolism, immune function, brain health, and chronic diseases like Parkinson’s. The discussion highlights advancements in microbiome science through AI, DNA sequencing, and personalized interventions. Both CEOs share insights on how probiotics, diet, and fasting can reshape the gut microbiome, underscoring the importance of individualized health approaches. The panel concludes with optimism about the future of microbiome research, including targeted antibiotics, new probiotics, and the growing acceptance of these therapies in clinical practice.
Our expert guests include the founders of two exciting startups in the Alumni Ventures portfolio:
- Colleen Cutcliffe from Pendulum Therapeutics, makers of a probiotic formulated with beneficial bacteria that naturally increases GLP-1.
- Leo Grady from Jona, providers of AI-Powered microbiome analysis to personalize food, diet, and lifestyle recommendations to improve health.
Our panel will separate scientific truths from common myths, providing you with actionable insights to improve your well-being.
Discover how Pendulum is pioneering new ways to make GLP-1 therapies more accessible by developing probiotics that offer the benefits of these treatments without the need for injections like Ozempic.
Learn how Jona is harnessing advanced sequencing technology and AI to provide simple, actionable health recommendations by analyzing your microbiome in the country’s leading lab and comparing it against over 60,000 peer-reviewed scientific papers to uncover links between your microbiome, diseases, conditions, symptoms, and the most effective steps you can take for better health.
This is a unique opportunity to learn from leading voices in health technology and venture capital and to understand the groundbreaking innovations shaping the future of the microbiome field. Whether you’re an investor, health enthusiast, or simply curious about the latest in health tech, this webinar is tailored for you.
Why You Should Watch:
- HomeGain insights from top experts in gut health and the microbiome.
- HomeLearn how Pendulum is revolutionizing GLP-1 therapies with probiotics.
- HomeDiscover how Jona is harnessing advanced sequencing technology and AI.
- HomeUnderstand the latest innovations and trends in health tech and how they can impact your health and investments.
Alumni Ventures is America’s largest venture capital firm for individual investors.
About your presenters
David has over 25 years of experience as an investor, adviser, and board member, with expertise across early- and late-stage venture capital. Before joining Alumni Ventures, David was Senior VP of Corporate Development and Business Development for DataXu, a marketer-aligned data and analytics company. Prior to his time at DataXu, he was a Director with the global venture and private equity firm 3i, including board directorships with ten companies. He also worked in the private equity group at GE Asset Management where he specialized in late-stage venture and growth capital opportunities. David received his BA in History from Yale in 1991 and an MBA from the Tuck School of Business at Dartmouth in 2000.
CEO and Co-Founder, Pendulum Therapeutics
Colleen Cutcliffe is the CEO and Co-Founder of Pendulum Therapeutics. Colleen has over 20 years of experience managing and leading teams in biotech, pharma and academia. Before starting Pendulum Therapeutics, Colleen served as the Senior Manager of Biology at Pacific Biosciences, which is where she met her two co-founders. Prior to that, Colleen was a Scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral research at Northwestern’s Children’s Memorial Hospital, received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and received her B.A. in Biochemistry from Wellesley College.
Founder and CEO, Jona
Leo has 20 years of experience leading development and commercialization of advanced machine learning, AI, computer vision, diagnostic and digital health technologies that have made a significant impact on healthcare practice. During his tenure as CEO of Paige, Leo led the company to become an industry leader, internationally launched several groundbreaking software products and became the first-ever company to receive FDA approval for an AI product in pathology. Leo is currently the founder and CEO of Jona and CEO in Residence with Breyer Capital.